CSL Ltd Delivered Decent FY 18 Financial Performance

Decent FY 18 Financial Performance: CSL Limited’s (ASX: CSL) stock rose 5.03% on August 15, 2018 after the company for FY 18 reported 29% growth in the reported net profit after tax to $1,729 million, slightly ahead of the company’s guidance. The company has delivered 2018 revenue growth of 11% at constant currency to $7,915 million, cashflow from Operations (CFO) up 53% to $1,902 million and  increased total full year dividend by 26% to $1.72 per share. Moreover, during FY18, Privigen sales grew 13% & Hizentra sales grew 12%, both at CC, and IDELVION is on track to become the standard of care for Haemophilia B patients. Specialty Products portfolio sales grew 24% at CC, due to an ongoing growth in Kcentra and launched HAEGARDA for patients with Hereditary Angioedema.

[optin-monster-shortcode id=”wxhmli4jjedneglg1trq”]

Additionally, for FY 19, CSL planned to open between 30 and 35 new collection centers and expects a modest increase in plasma costs, which will affect overall margin growth. For FY 19, CSL’s net profit after tax is expected to be in the range of approximately $1,880 to $1,950 million at constant currency, which reflects growth over FY18 of 10-14%. CSL stock has risen 14.01% in three months as on August 14, 2018.

Dividend Stocks To Buy

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.


The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.

6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report